Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Yesafili, received marketing authorization approval from the European Commission for the European Union
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
he company posted total income during Q2 FY24 at Rs. 12.86 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Subscribe To Our Newsletter & Stay Updated
